A human study to evaluate safety and effective dose of Seapolynol (Ecklonia cava extract) on postprandial glucose level in healthy subjects

Ewha Womans University0 个研究点目标入组 24 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•1) Subject who voluntarily agrees to participate and sign in informed consent form
•2) Age: 20 years = Age < 40 years
•3) fasting glucose < 126mg/dL
•4) Subject who can participate all visits after rondomization

•1) Continuous consumption of drug that affect glucose metabolism, inflammation, antioxidative capacity and lipid metabolism or dietary supplement or oriental medicine or within 4 weeks before the first visit
•2) Consumption of anticoagulant within 4 weeks before the first visit
•3) BMI=18.5 or BMI=30
•4) Following diseases :
•? Diabetes, liver dysfunction, renal dysfunction, cardiovascular diseases (hypertension, stroke, etc.), thyroid diseases
•? Mental diseases such as depression, schizophrenia, alcoholism , drug addiction
•? Wasting diseases such as malignant tumor etc., and severe muscular skeletal disease
•? asthma and allergic diseases
•5) Chronic smoker (= 20 cigarettes / day)
•6) Excessive exercise (= 10 hours / week)
•7) Change of body weight more than 4 kg or weight control within 4 weeks before the first visit
•8) Subjects with hypersensitivity to test materials
•9) Participation in other human study within 4 weeks before the first visit
•10) Pregnant or lactating women
•11) Any condition that the principal investigator believes may put the subjects at undue risk

发起方